NCT04816526View on ClinicalTrials.gov

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

August 4, 2022

Study Completion Date

November 3, 2022

Conditions
Myeloma Multiple
Interventions
BIOLOGICAL

Descartes 08

Car T-cells

Trial Locations (2)

37203

Sarah Cannon Research Institute at Tennessee Oncology, Nashville

92868

University of California Irvine, Orange

Sponsors
All Listed Sponsors
lead

Cartesian Therapeutics

INDUSTRY